Letters to the Editor  by unknown
Kidney International, Vol. 62 (2002), pp. 1474–1481
LETTERS TO THE EDITOR
2. Muntner P, He J, Hamm L, et al: Renal insufficiency and subsequentRenal insufficiency and the risk death resulting from cardiovascular disease in the United States.
J Am Soc Nephrol 13:745–753, 2002
3. Mann JF, Gerstein HC, Pogue J, et al: Renal insufficiency as aof cardiovascular mortality predictor of cardiovascular outcomes and the impact of ramipril:
The HOPE randomized trial. Ann Intern Med 134:629–636, 2001
4. Dries DL, Exner DV, Domanski MJ, et al: The prognostic implica-
To the Editor: Garg et al, in their recent analysis of tions of renal insufficiency in asymptomatic and symptomatic pa-
tients with left ventricular systolic dysfunction. J Am Coll Cardioldata from NHANES I in Kidney International, conclude
35:681–689, 2000that moderate renal insufficiency is not an independent
risk factor for cardiovascular or all-cause mortality in Reply from the Authors
the general population [1]. They performed a robust
We thank Drs. Reddan and Szczech for their letter.series of statistical analyses providing the rationale that
We place their statistical power comment into clinicalmoderate renal insufficiency may be a surrogate for other
context and clarify our opinion based on the recent publi-traditional cardiovascular risk factors. The significant as-
cation of NHANES II data [1].sociation between renal insufficiency and mortality in
NHANES I [2], NHANES II [1], Framingham [3] andunadjusted analyses not demonstrated in multivariable
eight other longitudinal studies (described in [2]) consis-analyses supports their rationale. What is puzzling is that
tently report that patients with moderate renal insuffi-a similar analysis of NHANES II (a similarly collected
ciency co-occurring with other established cardiovascu-but more contemporary data set) published one month
lar risk factors such as diabetes, hypertension, or olderearlier [2] arrived at a completely different conclusion,
age, or co-occurring with established cardiovascular dis-namely, that renal insufficiency was an independent pre-
ease, have a higher incidence of future cardiovasculardictor of both cardiovascular and all-cause mortality.
events and mortality. Given that patients with moderateWe believe these conflicting findings point to an alter-
renal insufficiency benefit from established cardiovascu-native explanation for the absence of an apparent rela-
lar protective interventions such as angiotensin-convertingtionship between renal insufficiency and cardiovascular
enzyme (ACE) inhibitors and 3-hydroxy-3-methylglu-disease from that offered by Garg et al [1]. The detection
taryl (HMG-CoA) reductase inhibitors, the importanceof a strong association of cardiovascular risk with renal
of using such interventions in these patients cannot beinsufficiency in populations with pre-existing cardiovas-
over emphasized. Using renal insufficiency ascertain-cular disease [3, 4] is facilitated by the increased statisti-
ment, as an important strategy by which patients arecal power conferred by higher cardiovascular event and
mortality rates in such populations. The non-detection identified for intervention application in health care de-
of an association by Garg et al [1] juxtaposed with the livery, remains to be clarified.
opposite findings of Muntner et al [2] in these two studies However, the literature is not consistent in the inter-
of the general population suggest that the relatively pretation of the inferred causal association between
lower cardiovascular event rates in the general popula- moderate renal insufficiency and cardiovascular disease,
tion conferred such an absence of statistical power on through potential unique mechanisms that become more
these studies and may have lead to a type II error and pronounced with glomerular filtration rates (GFR) de-
an erroneous conclusion in one of them. cline (such as elevated calcium phosphate product and
anemia, outlined in [2]). Three studies in the general
Donal N. Reddan and Lynda A. Szczech population [1–3] would now suggest that the indepen-Durham, North Carolina, USA
dent association between moderate renal insufficiency
Correspondence to Donal N. Reddan, M.D., Duke University Medical and cardiovascular disease is small or non-existent [haz-
Center, Institute for Renal Outcomes and Health Policy, Division of ard ratios and 95% confidence intervals (95% CI) of 1.7Nephrology, Durham, NC, USA.
(1.3 to 2.1), 1.2 (0.8 to 1.8) and 1.1 (0.8 to 1.4)]. NHANES
I, a negative study, had 99% power to detect a hazardREFERENCES
ratio greater than 2 (a statement which was reported in
1. Garg AX, Clark WF, Haynes RB, House AA: Moderate renal the initial submitted version of the manuscript, but theninsufficiency and the risk of cardiovascular mortality: Results from
was subsequently dropped in revisions). Any potentialthe NHANES I. Kidney Int 61:1486–1494, 2002
independent association between moderate renal insuf-
ficiency and cardiovascular disease in the general popula-
tion is much smaller than established cardiovascular risk 2002 by the International Society of Nephrology
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factors such as diabetes, hypertension, or smoking. Fur- membranoproliferative glomerulonephritis (MPGN)
with mycophenolate mofetil (MM) with complete remis-thermore, the independent association between moder-
sion. My patient was a 56-year-old Caucasion man whoate renal insufficiency and cardiovascular disease contains
presented with anasarca, a creatinine clearance of 56 mL/both causal and non-causal components. For example,
min, 16 grams of protein excreted in 24 hours, and ain longitudinal studies, peripheral arterial disease and
blood pressure of 194/112 mm Hg. After reducing hiscerebrovascular disease are often independently associ-
blood pressure with high-dose angiotensin-convertingated with future cardiac events, but such an association
enzyme (ACE) inhibitor, diuretics, and a nondihydropyi-is not causal. Similarly, a portion of the independent
dine calcium channel blocker, his creatinine clearance andassociation between renal insufficiency and cardiovascu-
proteinuria were unchanged. A renal biopsy revealedlar disease is non-causal and is due to factors such as
type I MPGN. Complement levels were reduced slightly,renal vascular disease and diuretic use, or is a reflection
but antibodies for hepatitis C (on two occasions), humanof established cardiovascular risk factor severity (out-
immunodeficiency virus (HIV), and systemic lupus eryth-lined in [2]). The contribution of non-causal factors to
ematosus were all negative. There was no response tothe independent association between renal insufficiency
80 mg prednisone. Within 1 week of instituting 750 mgand cardiovascular disease would be estimated to be
MM twice daily, the patient began to diurese, his bloodhighest in patients with pre-existing cardiovascular dis-
pressure medication requirements began to fall, and hisease and hypertension, and so quantifying the indepen-
sense of well-being returned. Within 2 months, he haddent association in the general population is valuable.
no proteinuria. One year after initiating therapy, his ena-These longitudinal studies of the general population sug-
lapril dose was 10 mg daily (down from 80 mg). He wasgest that the cumulative effect of all potential mecha-
taking 10 mg prednisone every other day and 500 mgnisms, by which moderate renal insufficiency may cause
MM twice daily. He was free of edema, he was excretingcardiovascular disease, is small. Consequently, these three
less than 100 mg protein/24 hours (repeatedly), his bloodlongitudinal studies should not be cited as evidence that
pressure was 124/72 mm Hg, and his creatinine clearancemoderate renal insufficiency is atherogenic and cardio-
as 98 to 106 mL/min. Thus, this case and that reportedmyopathic in a clinically meaningful way.
by Choi et al demonstrate that this previously difficult
Amit X. Garg, William F. Clark, to treat disease in the adult may respond when steroids
R. Brian Haynes, and Andrew A. House and MM are combined as therapy.
Hamnilton and London, Ontario, Canada
Murray L. LevinCorrespondence to Amit Garg, M.D., Ph.D. student, Clinical Epide-
Chicago, Illinois USAmiology and Biostatistics, McMaster University, Hamilton, Ontario,
Canada.
Correspondence to Murray L. Levin, M.D., Division of Nephrology/E-mail: amitg@mcmaster.ca
Hypertension, Northwestern University Feinberg School of Medicine,
210 East Pearson Street, #13B, Chicago, IL 60611 USA.
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Hemodialysis vascular access inMycophenolate mofetil
incident patients in Spaintreatment for primary
To the Editor: In his recent article on vascular ac-glomerular diseases
cesses in the prevalent hemodialysis population, Pisoni
et al [1] rightly pointed out that the type of access used is
To the Editor: I read with great interest the article by mainly determined by the preference of the professional
Choi et al Mycophenolate mofetil treatment for primary
glomerular diseases in a recent issue of Kidney Interna-
tional [1]. I, too, have treated one patient with type I  2002 by the International Society of Nephrology
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Table 1. Vascular access used for first hemodialysis in different ana´lisis de su distribucio´n, morbilidad y sistemas de monitorizacio´n.
types of centers in Spain during October and November 1999 Nefrologia 21:45–51, 2001
4. Grupo de trabajo para el estudio del acceso vascular de la sociedad
No. of Central Permanent Espanola de fefrologia: www.senefro.org
Institution patients catheter % access %
Hospital III 377 187 50 190 50
Hospital II 43 10 23 33 77 Reply from the Authors
Hemodialysis center 104 31 30 73 70
We thank Dr. Rodrı´guez for his comments. Our analy-P  0.00003
sis indicates that the differences in vascular access use
for Spanish incident patients between the Dialysis Out-
comes and Practice Patterns Study (DOPPS) and those
caring for these patients and is not so closely related reported by Dr. Rodrı´guez result from differences in
to the patients’ clinical or demographic characteristics. facility samples. The DOPPS was a stratified random
There is one datum in this excellent work, however, sample designed and executed to represent all of Spain
with which we must disagree. The article states that the and was obtained with a 95% acceptance rate, yielding
percentage of patients initiating hemodialysis in Spain a low probability of non-response bias [1, 2]. The DOPPS
with a central catheter as first access is estimated at 24%, sample reflects the different geographic regions and unit
when actually it is nearly double that figure. During 1997 types within Spain (i.e., 50% hospital-based, 50% satel-
to 2001, we performed three studies, one regional [2] and lite units).
two national [3, 4], demonstrating that the percentage of In contrast, neither facility sample described by Rodrı´-
patients who begin dialysis with a central catheter in our guez et al [3, 4] represents all of Spain. The first [3] is
country is 44 to 52%. In one of these studies we found limited to the region of Catalunya, which constitutes 15
that there were significant differences in the use of cen- to 20% of all hemodialysis patients in Spain. However,
tral catheters as first access according to the type of striking differences in vascular access use can exist across
center where hemodialysis was initiated [3]. Third-level regions of a country [5]. The second paper [4] reports
hospitals, where more than 70% of patients begin hemo- on a 1999 survey sent to all Spanish dialysis units. How-
dialysis (and are then transferred to other centers), im- ever, only 88 of the 300 units responded. This low
planted central catheters were used as first access in
response rate of 30% suggests the high possibility of a
over 50% of patients, whereas second-level hospitals and
biased, non-representative study sample. Furthermore,
dialysis centers used a lower percentage, as shown in
only 22% of these 88 responding units were satelliteTable 1.
units, in contrast to our determination that 50% of Span-The lack of a permanent access to begin hemodialysis
ish dialysis units are satellites. The results from Dr. Rod-is, unfortunately, a difficult problem to tackle and one
rı´guez and his colleagues are over-represented by Span-that will require imaginative solutions. One only has to
ish hospital units, which are more likely than satellitelook at the situation in Italy. Although the nephrologist
units to start new hemodialysis patients with catheters.intervenes in placement of the vascular access in 80%
Furthermore, the distribution of hemodialysis patientsof cases, it is one of the countries in Europe where central
by region was not representative of Spain in this samplecatheters are used more. It is clear that we have to direct
since 33% of prevalent patients were from Catalunyaall our efforts to resolving this situation to reduce the
and 5.7% from Madrid, while the populations of patientsmorbidity and mortality related to the use of temporary
for these two regions are approximately 17% and 11%,vascular accesses.
respectively.
Juan A. Rodrı´guez In summary, DOPPS results provide a representative
Barcelona. Spain. indication of vascular access use among hemodialysis
patients in Spain, while those of Rodrı´guez et al areCorrrespondance to Juan A. Rodrı´guez, M.D., Servicio de Nefrologı´a,
Hospital Universitario Vall d’Hebro´n, Paseo Vall d’Hebro´n 119-129, more likely to be unrepresentative estimates of true pop-
08035 Barcelona, Spain ulation values for Spain.
E-mail: telamon@redestb.es
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REFERENCES venous nimesulide. In 12-week-old animals the effect the
aspirin was greatly attenuated, emphasizing the special1. Pisoni RL, Young EW, Dykstra DM, et al: Vascular access use in
Europe and the United States: Results from the DOPPS. Kidney neonatal sensitivity to NSAIDs. The publication that
Int 61:305–316, 2002 ibuprofen may have less renal “toxicity” than indometh-
2. Young EW, Goodkin DA, Mapes DL, et al: The Dialysis Outcomes
acin in premature babies with PDA [5] is not supportedand Practice Patterns Study (DOPPS): An international hemodialy-
sis study. Kidney Int 57(Suppl 74):S74–S81, 2000 by the above-mentioned animal studies.
3. Rodrı´guez JA, Lopez J, Cleries M, et al: Vascular access for hemo-
dialysis – an epidemiological study of the Catalan Renal Registry. Alfred Drukker
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ana´lisis de su distribucio´n, morbilidad y sistemas de monitorizacio´n. Correspondence to Alfred Drukker, M.D., Ph.D., P.O. Box 8504,
Nefrologia 21:45–51, 2001 Jerusalem 91084, Israel.5. Hirth RA, Turenne MN, Woods JD, et al: Predictors of type of E-mail: Alfred@cc.huji.ac.ilvascular access in hemodialysis patients. JAMA 276:1303–1308, 1996
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1. Khan KNM, Paulson SK, Verburg KM, et al: PharmacologyFetal and neonatal renal of cyclooxygenase-2 inhibition in the kidney. Kidney Int 61:1210–
1219, 2002
2. Peruzzi L, Gianoglio B, Porcellini MG, et al: Neonatal end-aspects of cyclooxygenase stage renal failure associated with maternal ingestion of cyclooxy-
genase type-2 selective inhibitor nimesulide as tocolytic. Lancet
354:1615, 1999(COX) inhibition
3. Salame Chama N, Mosig D, Drukker A, Guignard JP: The renal
hemodynamic effects of ibuprofen in the newborn rabbit. Pediatr
Res 48:600–605, 2000To the Editor: In a recent issue of Kidney Interna- 4. Drukker A, Mosig D, Guignard JP: The renal hemodynamic ef-
tional, Khan et al, in the discussion of their article [1], fects of aspirin in newborn and young adult rabbits. Pediatr Nephrol
16:713–718, 2001cited that only a limited number of adverse effects of
5. Van Overmeire B, Smets K, Lecoutere D, et al: A comparison ofintrauterine cyclooxygenase (COX) inhibition on fetal
ibuprofen and indomethacin for closure of patent ductus arteriosus.
renal function are quoted and one is its immediate post- N Engl J Med 343:674–681, 2000
natal effect. Amazingly, the authors write that COX-2
inhibition “poses an uncertainty for obstetrical-gyne-
cological applications.” Abundant evidence now shows Reply from the Authors
that exposure of the human fetus to non-steroidal anti-
The fetal kidney is capable of synthesizing prostaglan-inflammatory drugs (NSAIDs) may cause severe renal
dins (PGs), and inhibiting the production of these PGsstructural changes, as well as affect fetal renal function
can decrease renal blood flow, increase renal vascularthrough their actions on renal perfusion. Suffice it to
resistance and cause other related functional and mor-quote a case report on the use of nimesulide during
phological alterations [1–3]. Therefore, we agree with Dr.pregnancy that resulted in a baby born with end-stage
Drukker that renal alterations seen in human fetusesrenal disease [2]. This aspect is particularly important
and babies exposed to non-steroidal inflammatory drugsbecause of the ever-increasing use of NSAIDs during
(NSAIDs) in the perinatal period are likely due to thepregnancy for the treatment of toxemia, premature la-
inhibition of cyclooxygenase (COX). Because NSAIDsbor, and polyhydramnios.
inhibit both isoforms of COX (COX-1 and COX-2) equi-Not less important are the neonatal aspects of the use
potently, it is not clear whether these fetal renal effectsof NSAIDs, especially in pre-term infants. Since 1976,
are due to the inhibition of COX-1, COX-2, or both iso-repeated intravenous boluses of indomethacin are used
forms. High expression of COX-2 is observed in the hu-for the pharmacological closure of patent ductus arte-
man fetal kidney during the third trimester [4]. This, alongriosus (PDA). Many publications have pointed to the
with the renal pathology seen in COX-2 knock-out mice(fortunately often temporary) occurrence of acute renal
and in neonatal rat kidneys exposed to selective COX-2failure as a result of this treatment. A recent study in
inhibitors, suggests a role for COX-2 and its metabolites1-week-old rabbits shows that an intravenous bolus of
in fetal renal functions and nephron maturation [5].aspirin, ibuprofen, and indomethacin causes a remark-
In comparison to non-selective NSAIDs, selectiveably similar very significant fall in renal blood flow
COX-2 inhibitors (celecoxib, rofecoxib, valdecoxib, and(RBF), and glomerular filtration rate (GFR) with a rise
parecoxib sodium) were introduced into clinical medi-in renal vascular resistance (RVR) [3, 4]. Preliminary
cine more recently. To the best of our knowledge, theredata indicate the same neonatal renal response to intra-
are no reports available that describe fetal renal alter-
ations arising from the use of these selective COX-2
inhibitors in humans. However, until there is adequate 2002 by the International Society of Nephrology
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clarification of the roles of COX isoforms in the develop-
ment of the human kidney, we believe that uncertainty
exists in the obstetrical-gynecological use of any COX-2
inhibitor, either selective or non-selective.
K. Nasir M. Khan, Susan K. Paulson, James Lefkowith,
Kenneth Verburg, and Timothy Maziasz
Skokie, Illinois
Correspondence to K. Nasir Khan, D.V.M., Ph.D., Pharmacia Re-
search and Development, 4901 Searle Parkway, #1128, Skokie, Illinois
60077, USA
E-mail:nasir.k.khan@pharmacia.com
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The development of
hypertension in
acute and chronic
renoparenchymal diseases
To the Editor: In the March 2002 issue of Kidney
International, Dr. Juncos discusses a rather neglected
topic in nephrology, the development of hypertension
in acute and chronic renoparenchymal diseases [1].
One of the most obvious questions, actually the first
to be addressed by the discussant, is whether there is
evidence from animal models or human disease that the
incidence and severity of hypertension vary in different
types of glomerulonephritis at similar levels of glomeru-
lar filtration rate (GFR). A clear and convincing answer
to this question would be of great value. In fact, if it
were possible to show that a particular renal lesion has
a greater propensity to cause hypertension, we could
understand considerably more of the renal mechanisms
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hypertension in gomerular disease. Am J Nephrol 9(Suppl 1):85–behind hypertension, not only in kidney disease, but also
90, 1989
in the more common hypertension of genetic origin. On 7. Eto T Yamamoto Y: Fujimoto S, et al: Factors contributing to
blood pressure levels in chronic glomerulonephritis: An analysispage 1188 of the discussion, Dr. Juncos says that he is
of 105 biopsied patients. Nephron 55:129–132, 1990unaware of any study specifically designed to compare
8. Johnston PA, Davison AM: Hypertension in adults with idio-
the incidence or severity of hypertension in different pathic glomerulonephritis and normal serum creatinine. A report
from the MRC Gomerulonephritis Registry. Nephrol Dial Trans-forms of glomerulonephritis. Actually, several groups,
plant 8:20–24, 1993including my own, have pubished on this particular issue
9. Kheder MA, Ben Maiz H, Abderrahim E, et al: Hypertension in
[2–11] (Table 1). primary chronic gomerulonephritis. Analyis of 359 cases. Nephron
63:140–144, 1993Even if the heterogeneity of the studies precludes any
10. Vujic D, Djukanovic LJ, Petrovic M, Radmilovic A: Arterialfirm conclusion, as can be seen in patients with normal hypertension in patients with primary glomerulonephritis. Srp Arh
renal function (Table 1), glomerular sclerotic lesions are Celok Lek 121:8–12, 1993
11. Heaf J, Likkegaard H, Larsen S: The epidemiology and prognosisreported as the most frequent hypertension associated
of glomerulonephritis in Denmark 1985–1997. Nephrol Dial Trans-(three of four studies), while this trend is less evident, plant 14:1889–1897, 1999
but still present, with advancing renal failure (Table 1). 12. Konishi Y Okada N: Okamura M, et al: Sodium sensitivity of blood
pressure appearing before hypertension and related to histologi-This association could suggest that a decrease in the
cal damage in immunoglobulin A nephropathy. Hypertens 38:81–
available filtration area is the lesion more likely to initi- 85, 2001
13. Minetti E, Stellato T, Guidi E: Primary focal and segmentalate a series of events that lead to hypertension. Whether
gomerular sclerosis and bood pressure. Do familial hypertensionthese events trigger a compensatory increase of filtration
or established hypertension modify the progression of the disease?
pressure, by activation of the tubuloglomerular feed- J Nephrol 3:155–162, 1990
14. John RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbeback, afferent arteriolar dilatation, efferent arteriolar
B: Suble acquired renal injury as a mechanism of salt-sensitiveconstriction, or all of these together, we do not know.
hypertension. New Engl J Med 346:913–923, 2002
However, Konishi et al recently showed that in patients
with IgA nephropathy, normotensive and with normal Reply from the Author
renal function, a sodium sensitivity index is related to I thank Dr. Guidi for his interest in my Forum dis-
glomerulosclerosis [12]. We went a bit further by dis- cussion on “Intrarenal Mechanisms of Salt and Water
covering, in these same patients, that familiality for hy- Retention in Glomerulonephritis,” and particularly be-
pertension contributed to the severity of hypertension, cause of Dr. Guidi’s many contributions to the field of
determined as need of antihypertensive therapy [13]. glomerulonephritis (GN) and arterial hypertension. I re-
These results could renew the research on renal inter- gret that my answer to Dr. Madias’ first question led to
mediate phenotypes and hypertension [14], a field rather a misinterpretation by Dr. Guidi. I concur that there are
neglected recently, owing to the great expansion of ge- several studies dealing with the prevalence of hyperten-
nome studies, believed, perhaps unwisely, in such an intri- sion in different forms of GN [1–4]. However, in my
cate field, to yield quick and definitive answers. opinion, none of these studies were specifically designed
in a manner which can address this question directly.
Ettore Guidi
Having said this, however, it is important to point outMilan, Italy
that this kind of study is extremely difficult if not impossi-
Correspondence to Ettore Guidi, M.D., Clinical Research Center in ble to perform. In fact, a rigorous protocol design would
Nephrology-Hypertension, Ospedale Niguarda Ca’Granda, via Farini require to know the blood pressure of all the subjects9, 20154, Milan, Italy.
before and after they contracted GN, since many of theE-mail: etguid@tin.it
patients could have had undiagnosed essential hyperten-
sion. In children this may be less important but not inREFERENCES
the older populations since the incidence of hypertension
1. Juncos LI: Intrarenal mechanisms of salt and water retention in
increases with age. This is evident in the paper by John-the neprotic syndrome. Kidney Int 61:1182–1195, 2002
ston and Davidson [1] who concluded they might have2. Vendemia F, Fornasieri A, Veslis O, et al: Different prevalence
rates of hypertension in various renoparenchimal diseases, in Sec- been “observing two separate processes” (essential hy-
ondary Forms of Hypertension, New York, London, Toronto, Syd- pertension and GN) in the same population. Similarlyney, San Francisco, Grune & Stratton, 1981, pp 89–94
Orofino et al [2] found that excluding patients with ab-3. Danielsen H, Kornerup HJ, Olsen S, Posborg V: Arterial hyper-
tension in chronic gomerulonephritis. An analysis of 310 cases. normal renal function, the hypertension rate in patients
Clin Nephrol 19:284–287, 1983 with GN was equal to the control population. In the 359
4. Guidi E, Magni, Barbiano di Belgiojoso G, et al: Blood pressure
cases of primary GN studied by Kheder et al [3] thein patients with four different primary glomerulonephritis. Clin
Exp Hypertens A6:1357–1366, 1984 mean age was 37 years and a large portion (Fig. 1 in the
5. Orofino L, Quereda C Lamas S, et al: Hypertension in primary paper) was over 40 years of age. Thus, excluding essential
chronic glomerulonephritis: Analysis of 288 biopsied patients.
hypertension seems imperative. To this consideration,Nephron 45:22–26, 1987
6. Ritz E, Rambausek M, Hasslacher C, Mann J: Pathogenesis of we might add that patients who may normally have had
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low blood pressure, after contracting their GN may have highly associated with hypertension. Indeed the litera-
ture yields plenty of support for this view and surely ithad an increase in their blood pressure without reaching
levels which we standardly would consider to be hyper- will be interesting to learn the mechanisms by which
glomerulonephritis, glomerular sclerosis, or tubular in-tensive and thus, these patients would go overlooked as
well. A second major limitation is the power of these terstitial lesions (as suggested by Johnson et al) [7] lead
to what appears to be mainly enhanced sodium retentionstudies, even in the larger ones which have recruited
200–300 patients. Once we divide them up into the differ- at the level of the cortical collecting duct as well as
altered vascular reactivity. I again thank Dr. Guidi forent diagnosis, one is left with a very small number of
hypertensive patients in each group, thus making it risky his comments.
to draw conclusions. For instance, Eto et al [5] correlated
Luis I. Juncoshypertension with only 5 type of lesions and yet, the
Cordoba, Argentinaactual number of hypertensives per histological diagnosis
ranged from 3 to 7. Moreover, the few hypertensive Correspondence to Luis I. Juncos, M.D., I.P.E.M. Gambro Health-
care, IV Department of Medicine, National University of Cordoba,patients were older and more obese, making the associa-
Colon 4154, Cordoba 5003, Argentina.tion between hypertension and the histological pattern E-mail: luisjunc@satlink.com.ar
harder to trust. Despite these limitations, the studies
mentioned by Dr. Guiddi do provide important informa- REFERENCES
tion. In my response to Dr. Madias, I very briefly men-
1. Johnston PA, Davison AM: Hypertension in adults with idiopathictioned this, but I obviously did not give the subject the glomerulonephritis and normal serum creatinine. A report from
attention it deserves and thus will take this opportunity the MRC Glomerulonephritis Registry. Nephrol Dial Transplant
8:20–24, 1993to expand on this. The first four references [1–4] are
2. Orofino L, Quereda C, Lamas S, et al: Hypertension in primaryretrospective studies that examine the prevalence of hy- chronic glomerulonephritis: Analysis of 288 biopsied patients. Neph-
pertension in distinct forms of GN. Guiddi’s study [4] ron 45:22–26, 1987
3. Kheder MA, Ben Maiz H, Abderrahim E, et al: Hypertension insuggested that obliterating lesions tended to correlate
primary chronic glomerulonephritis. Analysis of 359 cases. Nephronmore with the presence of hypertension. They found a 63:140–144, 1993
prevalence rate (based on anti hypertensive therapy) of 4. Guidi E, Magni M: Barbiano di Belgiojoso G, Minetti L, et al:
Blood pressure in patients with four different primary glomerulone-25%, 41%, 49%, and 60% in patients with IgA nephrop-
phritis. Clin Exp Hypertens A6:1357–1366, 1984athy, acute GN, membranous GN, and focal sclerosis 5. Eto T, Yamamoto Y, Fujimoto S, et al: Factors contributing to
respectively. Similarly, in the study of Orofino et al, focal blood pressure levels in chronic glomerulonephritis: An analysis of
105 biopsied patients. Nephron 55:129–132, 1990sclerosis ranks first in hypertension prevalence (30%).
6. Danielsen H, Kornerup HJ, Olsen S, Posborg V: Arterial hyper-Danielsen et al [6] also reports glomerular sclerosis as tension in chronic glomerulonephritis. An analysis of 310 cases. Clin
the lesion more frequently associated with hypertension Nephrol 19:284–287, 1983.
7. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe(88%) This study however included patients with renal
B: Subtle acquired renal injury as a mechanism of salt-sensitivefailure (some on hemodialysis), which may explain the hypertension. N Engl J Med 346:913–923, 2002
high overall prevalence of hypertension (61%) and why
so many patients had more aggressive forms (malignant
hypertension, hypertensive retinopathy, left ventricular
hypertrophy, etc.). Nonetheless, other studies show higher The effect of vitamin A onprevalence of hypertension in other conditions such as
mesangiocapillary GN’s [1, 5]. All of these studies are the course of infective andlimited by the restrictions noted above, particularly the
lack of blood pressure data prior to the development of non-infective renalthe disease as well as the fact that there was no standard-
ization for the method of checking blood pressure (a inflammationmatter of concern as discussed by Guiddi et al) thus,
making it difficult to firmly establish the prevalence of
hypertension in GN. All in all, I believe the above studies To the Editor: We read the article of Schaier et al
offer very important data and overall show that hyper- related to the effect of isotretinoin in rat chronic glomer-
tension occurs during GN more often than would be ulonephritis with great interest [1]. The effects of reti-
expected by sheer chance. However, conclusions regard- noids on the development of renal tissue and inflamma-
ing the prevalence of hypertension must be viewed with tory renal lesions have gained interest recently. After
caution as studies as these can not be designed to look we demonstrated the relation of the extent of renal scar-
specifically at this question because of the inherent limi-
tations mentioned above. This concept does not preclude
Dr. Guiddi’s notion that glomerular sclerotic lesions are  2002 by the International Society of Nephrology
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ring to serum vitamin A levels in children with recurrent ably different. However, our findings were consistent
with that of Schaier et al [1].urinary tract infections [2], we also performed an experi-
Retinoids are effective in pyelonephritic (infective)mental study showing the effect of vitamin A in alleviat-
[3] and glomerulonephritic (non-infective) [1] inflam-ing the renal scarring in rat acute pyelonephritis [3].
mations in renal tissue. However, it is early to state theNext, we evaluated the effect of vitamin A on ablation
presence of a similar effect in ablation nephropathy, andnephropathy and found that while a low dose of vitamin
further studies with different degrees of ablation andA was not effective in preventing glomerulosclerosis,
different doses of vitamin A are needed.a high dose of vitamin A caused even progression of
glomerulosclerosis in this model of nephropathy [4].
Salih Kavukc¸u, Alper Soylu, and Mehmet Tu¨rkmenOur studies were preliminary in design and not so Izmir, Turkey
sophisticated as that of Schaier et al. However, the con-
Correspondence to Salih Kavukc¸u, M.D., Dokuz Eylul Universitytrol group used by Schaier et al included only rats with
Medical Faculty, Department of Pediatrics, Mithatpas¸a Cad. No:665/4,
unilateral (1/2) nephrectomy. In that study, the rats were 35280 Ku¨c¸u¨kyalı´, I˙zmir, Turkey
E-mail:s.kavukcu@deu.edu.trdivided into three groups. One group was given only the
carrier of retinoid and the second and third groups were
REFERENCESgiven low and high doses of isotretinoin as a retinoid
derivative, respectively. The results indicate that there 1. Schaier M, Lehrke I, Schade K, et al: Isotretinoin alleviates renal
damage in rat chronic glomerulonephritis. Kidney Int 60:2222–2234,are no significant differences with respect to blood pres-
2001
sure, proteinuria, and histomorphologic and histochemi- 2. Kavukcu S, Turkmen M, Sevinc N, et al: Serum vitamin A and -
carotene concentrations and renal scarring in urinary tract infec-cal characteristics of the kidneys among the rats given
tions. Arch Dis Child 78:271–272, 1998low and high doses of isotretinoin [1]. In our study, we
3. Kavukcu S, Soylu A, Turkmen M, et al: The role of vitamin A
used vitamin A as the source of retinoid, and the doses in preventing renal scarring secondary to pyelonephritis. BJU Int
83:1055–1059, 1999of vitamin A, the degree of renal ablation (5/6 subtotal
4. Soylu A, Kavukcu S, Sarioglu S, et al: The effect of vitamin Anephrectomy) and thus the size of residual nephron num- on course of renal ablation nephropathy. Pediatr Nephrol 16:472–
476, 2001ber, and the duration of the experiment were consider-
